Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

免疫原性医学打开标签免疫 2019年冠状病毒病（COVID-19）免疫学临床试验病毒学内科学免疫系统传染病（医学专业）疾病

作者

Carl S. Goodyear,Amit K. Patel,Eleanor Barnes,Michelle Willicombe,Stefan Siebert,Thushan I. de Silva,John A. Snowden,Sean H. Lim,Sarah Bowden,Lucinda Billingham,Alex Richter,Miles W. Carroll,Edward J Carr,Rupert Beale,Daniel Rea,Helen Parry,Sarah Pirrie,Zixiang Lim,Jack Satsangi,Susanna Dunachie,Gordon Cook,P.D. Miller,Neil Basu,Ashley Gilmour,Anne-Marie Hodgkins,Lili Evans,A. HUGHES,Stephanie Longet,Georgina Meacham,Kwee Yong,Matthew J. Ahearne,Mickey Koh,Siobhan O. Burns,Kim Orchard,Caron Paterson,Graham McIlroy,Sam M. Murray,Tina Thomson,Stavros I. Dimitriadis,Lyndsey Goulston,Samantha Miller,Victoria Keillor,Maria Prendecki,David Thomas,Amanda Kirkham,Iain B. McInnes,Pamela Kearns,Richard Beesley,Vicky Churchill,Elspeth Insch,Holly Loughton,Emily MacDonald,Siân Lax,Faye Lowe,Sophia Magwaro,Mark Gradwell,Francesca Kinsella,Hayley Rolfe,Stacey McIntyre,Paige M Mortimer,Saly Al‐Taei,Susan Tadros,Sarita Workman,Maxine Arnott,James B. Brock,Andrew Melville,Aurélie Najm,Matthew J. Rutherford,Flavia Sunzini,Lou S Herman,Agnieszka Hobbs,Martina Ragno,Mary Wu,Rick Selby,Jennifer Clay,Clare Hutchison,Robert Lown,May Lwin,Naomi Meardon,Peter Kelleher,Liz Lightstone,Thomas P. Walters,Jane Denyer,Reham S. Ibrahim,Sarah Gleeson,Paul Martin,Stephen P. McAdoo,Helena Baker,Sarah Horswill,Nina Parungao,Stephen Saich,James Cullinane,Sophie Irwin,Paul Klenerman,Thomas Marjot,Ronjon Chakraverty,Christopher Holroyd,J. Kavi,Doreen Trown,Gavin Babbage,Julia Chackathayil,Patricia Faria,Kenneth C. Ingham,Murad Miah,Mauro Miranda,Nicola O’Reilly,Callie Smith,Kimberley Driver,Kaylee Gauntlett,Andrew G. Farthing,Sean D. Rundell,Emily Smith,A. Tong,Kieran Woolcock,Daniel Hanke,Stephen M. Laidlaw,Zainab Malik,Dung Nguyen,Nicholas M. Provine,Tom Tipton,Victoria Walker

出处

期刊：The Lancet Rheumatology [Elsevier BV]
日期：2024-06-01 卷期号：6 (6): e339-e351 被引量：1

链接

nih.govdoi.org

标识

DOI：10.1016/s2665-9913(24)00065-1

摘要

The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE DUO trial aimed to determine the value of third vaccinations in a wide range of patients with primary and secondary immunodeficiencies.

求助该文献

最长约 10秒，即可获得该文献文件

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

今日热心研友